阿托伐他汀对急性冠脉综合征患者介入治疗后C反应蛋白和尿酸水平的影响

目的:探讨阿托伐他汀对急性冠脉综合征(actue coronary syndromes,ACS)患者介入治疗后血清C反应蛋白(C_reactive protein,CRP)、尿酸(uric acid,UA)及血脂水平的影响。方法:对47例ACS患者介入治疗后进行不同剂量阿托伐他汀治疗,观察服药前后血清CRP、UA和血脂浓度的变化,并进行各组比较。结果:应用阿托伐他汀治疗后,各组CRP、UA、胆固醇(total cholesterd,TCH)、甘油三酯(triglycerin,TG)、低密度脂蛋白水平显著降低,高密度脂蛋白(high_density lipid protein,HDL)水平明显升高。20 mg剂量组疗效更为显著。结论:阿托伐他汀20 mg/d较10 mg/d能使经皮冠状动脉干预(percutaneous coronary intervention,PCI)术后CRP及UA进一步下降。

Effection of atorvastatin on levels of C-reactive protein and uric acid after percutaneous coronary intervention of acute coronary syndromes

Objective: To investigate the effects of atorvastatin on C-reactive protein,uricacid and blood lipids in acute coronary syndromes patients after percutaneous coronary intervention.Methods: Different does of atorvastatin were gaiven to 47 acute coronary syndromes patients after percutaneous coronary intervention.The changes of plasma concentration of C-reactive protein,uric acid and blood lipids were detected before and after medication.Results: The plasma C-reactive protein,the serum uric acid and cholesterol,triglycerin,low-densitylipid protein were significantly decreased after atorvastatin administration;whereas high-density lipid protein imperatively increased.The curative effect of atorvastation 20mg were more greatly significant.Conclusion: Atorvastatin 20 mg reduces CRP and UA levels to a greater extent than atorvastatin 10 mg daily does.